Sumary of Oral targeted therapy found to be an effective treatment option for high-risk hairy cell leukemia:
- The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G.
- Hairy cell leukemia is a rare form of B-cell blood cancer that is diagnosed in 600 to 800 people annually in the United States.
- There is a critical unmet need for therapy options in this subset of patients to achieve long-term cancer control.
- however, ibrutinib is FDA approved for the treatment of certain cancers, including mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma and others.